CHAPTER III



RESULTS

In order to study the relative of oxytocin (Syntocinon) dosage and plasma bilirubin level in infants, among control and subject groups, the infants were separated into 3 groups according to dose which each mother had received before their delivery. All relevant aspects were shown in table 4, 5 and 6; and were summerized in table 7. Most of them remained healthy and well during the period of the study. No blood group and Rh factor incompatibility between infants' and mothers' blood. Mean birth weight and mean gestational ages were similar in the subject and control groups, so that they did not gave the different effect on bilirubin levels of infants in this study.

Mean packed cells volume (hematocrit) were lower from the first day to the third day in each group of infants. It showed some difference when compared between groups.

rubin concentration in all babies in 24 hours, 48 hours and 72 hours of ages. In control group, the most frequency bilirubin concentration in the first day were at 4-5 mg.%, 7-8-mg.% in the second day, and 9-10 mg.% in the third day. In subject I group, the most frequency of bilirubin concentration were 5-6 mg.% in the first day, 8-9 mg.% in the second day, and 10-11 mg.% in the third day. In subject II group,

the most frequency of bilirubin concentration were 7-8 mg. % in the first day, 8-10 mg.% in the second day, and 11-12 mg.% in the third day. From this result, the frequency concentration of bilirubin in blood were different in all three group. In subject II group, the bilirubin level showed higher than level in subject I and control groups.

Figure 12 and 13, showed the comparison of mean serum bilirubin between control and subject groups. There were higher difference showed in figure 13 than in figure 12 in all three days of life.

Table 8 and 9 showed the relation of oxytocin dosage to the incidence of hyperbilirubinemia. The use of oxytocin during labour was found to influence the neonatal serum bilirubin level.

In comparison of total bilirubin levels between control and subject I group, there were the significant difference in 24 hours (P/0.001), and 48 hours (P/0.01), but no significant difference in 72 hours of ages (P(0.05)).

In comparison of total bilirubin levels between control and subject II group, there were significant difference in 24 hours (P/0.001) 48 hours (P/0.001), and 72 hours of ages (P/0.01). Of 16 infants in subject II group, 3 developed hyperbilirubinemia (18.75%) (total bilirubin level was more than 14.75 mg.%) and required phototherapy.

Figure 14 showed the comparison between mean serum bilirubin levels on the first, second and third days in the subject I group (received oxytocin mixture less than 4,000 mU,) and subject II group

(received oxytocin mixture more over 4,000 mU.).

Table 10 showed the difference between bilirubin levels in subject I and subject II groups. There was no significant difference in bilirubin level in age 24 hours ($P \ge 0.05$), but they showed significantly difference in age 48 hours ($P \le 0.01$), and 72 hours ($P \le 0.05$).

Table 11, 12 and 13 summerized prescribed drugs which all mothers had received 3 months before delivery. Some mothers took combinations of drugs ranged 1 to 7 drugs, average 4 drugs. The most commonly used drugs were prenatal vitamin with mineral such as Satibon[®] (40.59%), Fero-B-Cal (33.66%), etc., which they showed no effect on plasma bilirubin level of neonates.

ศูนย์วิทยทรัพยากร จหาลงกรณ์มหาวิทยาลัย

Table 4. Data of control group.

	Mot	her!s		gestational ages (week)	gravida		Ţ1	nfant'	S		mg.% ilirub es (ho	in	се	Packed 11s vo s (hou	01.
no.	age	bl. gr.	Rh fact.	gest ages	gra	sex	bl. gr.	Rh fact.	body wt.	24	4,8	72	24	48	72
1.	29	В	+	40	1	F	.,	+	2,850	5.5	8.5	11.5	59	. 55	47
2.	31	В	+	39	3	F	AB	+	2,650	3.5	6.8	8.7	69	54	56
3.	18	0	+	40	1	F	0	+	2,620	3.8	8.0	10.2	83	65	63
4.	20	A	+	42	2	М	0	. +	3,030	5.0	9.4	10.8	82	64	57
5.	24	AB	+	42	1	М	В	+	2.,770	4.0	7.8	11.2	75	60	59
6.	19	0	+	40	3	F	0	+	3,240	3.4	8.5	9.5	77	· 65	64
7.	25	AB	+	40	1	F	В	// + /	2,950	5.5	9.0	11.5	65	52	50
8.	33	0	+	38	3	F	0	+	2,850	3.8	8.0	11.0	80	61	60
9.	20	В	+	40	1	F	0	+ .	3,050	4.5	7.5	10.0	.77	60	60
10.	31	В	+	40	3	F	0	+	3,160	3.3	7.4	8.2	75	65	62
11.	25	В	+	40	1	М	В	+	3,080	3.0	9.0	12.9	82	66	60
12.	18	В	+	38	1	F	0	+	3,100	4.9	8.0	11.0	65	56	55
13.	23	А	+	1 39	1	F	A	+	2,800	2.8	6.2	9.0	72	63	60
14.	20	0	+	39	1	М	0	,+	3,020	3.7	9.0	10.6	75	64	60

Table 4. (cont.) Data of control group

	Moth	er's		gestational ages (week)	iḍa		. In	fant's		bil	mg.% irubir		cell	acked s volu	-
		b1.	Rh	gesta. ages	graviģa		bl.	Rh	body wt.	age	s (hou	ır)	age	s (hou	ır)
no.	age	gr.	fact.	. ge	60	sex	gr.	fact.	(gm.)	24	48	72	24	48	72
15.	30	В	+	40	2	M	В	+	3,470	5.5	7.0	8.2	73	67	57
16.	25	В	+	39	2	М	В	+	3,480	4.5	6.0	7.5	72	63	57
17.	19	В	+	40	1	М	В	+	3,830	5.8	9.4	10.3	61	61.	59
18.	24	В	+	38	1	F	В	+	2,880	6.4	9.5	11.5	69	58	57
19.	25	В	+	40	1	F	AB	+	3,250	4.5	7.5	9.0	71	65	56
20.	26	Α	+	40	1	М	A	+	3,210	1.5	6.4	8.0	72	65	56
21.	26	0	+	39	2	М	0	+	3,060	6.0	7.5	8.75	52	52	52
22.	23	Α	+	40	2	М	Αi	+	3,300	6.0	8.25	9.7	58	57	55
23.	18	0	+	40	1	М	0	+	2,500	6.2	9.5	10.0	64	62	57
24.	25	0	+	39	2	F	0	+	3,050	5.2	6.3	6.75	52	48	46
25.	10	В	+	39	1	F	АВ	e	2,590	4.2	4.75	7.0	56	55	51
26.	35	0	+	40	1	F	0	+	3,060	3.6	8.1	11.0	58	49	46
27.	29	Ö	+	39	1	М	0	+	3,00	5.8	8.5	9.5	62	57	54
28.	28	АВ	/+	39	1	М	AB	+	2,700	2.5	8.5	9.4	. 83	77	66

Table 4. (cont.) Data of control group.

				k)				V0.00	,		ng.% irubin			Packe s volu	
	Mot	her's		gestational ages (week)	ida		Iı	ıfant'	S	ag	es (ho	ur)		es (ho	
no.	age	bl. gr.	Rh fact.	gesta	gravida	sex	bl. gr.	Rh fact.	body wt. (gm.)	24	48	72	24	48	72
29.	18	0	+	38	1	F	0	+	2,700	6,6	9.1	13.25	67	65	53
30.	28	A	+	42	2	М	A	+	2,620	4.7	7.6	10.2	71	60	. 52
31.	22	0	+	40	2	F	0	+ .	3,150	5.5	9.2	10.0	63	58	57
32.	20	A	, + , .	39	2	F	0	+	3,240	4.1	6.6	11.5	80	65	60
33.	18	В	+	39	1	F	В	+	3,510	3.8	5.2	7.5	59	57	53
34.	20	0	+	40	2	М	0	** ***	3,500	3.5	6.75	8.0	56	54	53
35.	24	0	+	42	2	М	0	+	3,390	4.1	7.0	8.0	43	40	39
		,	+	40	2	F	0	+	3,460	4.0	6.8	9.0	78	64	56
37.	24	В	+	40	2	М	В	+	3,050	1.2	.7.2	8.8	82	66	62
38.	22	0	+	39	2	М	0	+	3,000	3.5	. 7.0	9.0	67	55	51
39.	23	Α	+	40	2	F	Α	+	2,750	5.7	8.0	9.5	66	58	54
40	20	В	+	38	1	F	0	+	3,210	2.8	7.8	10.5	81	65	- 65
41.	23	0	+	40	1	М	0	+	2,850	5.5	8.2	9.5	71	55	51
42.	25	В	+	38 .	3	М	В	+	3.650	2.5	7.6	9.2	78	65	64

Table 4. (cont.) Data of control group.

	Me	ther'		tional (week)	4					b	mg.% ilirub	in		Packed s volu	
-	MIC	orner.	S	atio (we	gravida		, l	nfant'	S	age	es (ho	ur)	age	s (hou	ır)
no.	age	bl. gr.	Ŗh fact.	gestational ages (week)	gra	sex	bl. gr.	Rh fact.	body wt. (gm)	24	48	72	24	48	72
43.	20	0	+	40	1	М	0	+	3,800	4.5	8.0	10.4	68	61	57
44. ⁻	23	A	+	40	2	M	A	+	. 3,500	4.2	6.7	10.0	75	69	64
45.	33	A	+	39	2	М	Α	+	3,370	4.5	6.9	8.4	72	56	52
46.	24	В	+	39	1	М	В	+	2,850	5.6	6.3	7.0	70	68	66
47.	25	В	+	41	1	F	В	+	2,600	4.0	6.5	6.8	80	72	60
48.	23	0	+	41	1	F	0 .	/ +	3,140	4.5	6.1	7.5	68	66	65
49	29	A	+	39	2	F	AB	+	3,640	5.6	7,6	9.7	64	49	44
50.	21	В	+	40	1	М	0	+	2,950	3.0	7.0	9.0	63	. 48	47
51.	26	A	+	38	2	F	В	. +	3,180	5.0	7.3	9.5	71	59	56

Table 5. Data of subject I group.

	Mot	her's	5	gestational ages (week)	grivada		· I:	nfant's			ml.% ilirubi es (hou	····	cel	Packe ls vol	ume	ml. Oxytocin
no.	age	bl. gr.	Rh fact.	gesta	gri	sex	bl. gr.	Rh fact.	body wt.	24	48	72	24	48	.72	0xy
1.	26	AB	+	38	1	F	AB	+	2,840	8.2	11.3	11.5	65	61	56	100
2.	23	В	+	39	1	F	В	+	3,130	4.3	7.1	8.7	67	55	52	300
3.	25	В	+	39	2	М	В	+	3,320	4.5	8.8	10.0	62	51	47	300
4.	27	В	<u></u> +	. 42	, 2	М	В	+	3,570	2.2	8.2	12.1	83	63	55	300
5.	19	В	+	\$@	0	F.	В	+	3,460	4.5	6.6	10.5	,68 ¹	5	56	300
6.	24	В	+	39	2	М	В	+	3,030	5.0	7.8	10.5	69	56	50	300
7.	25	AB	+	42	2	F	Α	+	3,240	4.5	6.5	7.0	61	55	53.	300
8.	25	0	+ .	41	1	F	0	+	2,880	5.3	8.5	9.8	67	62	60	250
9.	26	В	+	40 -	- 2	М	0	+	3,400	5.2	7.8	9.9	65	57	56	200
10.	24	0	+	40	3	М	0	+	3,800	3.5	8.5	9.8	78	66	58	100
11.	28	В	+	40	1	·M	0	+	3,880	5.2	9.7	11.0	62	49	49	100
12.	24	В	+	39	1	F	В	+	2,900	6.0	8.8	11.0	70	70	57	250
13.	25	A	+	40	2	F	0	+	3,480	4.2	7.3	10.6	75.	74	65	150
14.	24	В	+	40	3	F	Α	+	3,060	6.5	9.5	13.0	53	42	42	100

Table 5. (cont.) Data of Subject I group.

,	Mot	her's		gestational ages (week)	gravida		In	fant's			m1.% lirubi		cell.	Packed s volu	me	ml. Oxytocin
no.	age	bl. gr.	Rh fact.	gesta ages	gra	sex	bl.	Rh fact.	body wt.	24	48	72	24	48	72	0xy
15.	26	0 -	+	40	2	F	0	+	3,150	4.5	7.7	9.5	70 -	62	53	100
16.	28	В	+	41	3	М	В	+	3,550	3.8	7.0	9.4	65	47	47	200
17.	24	В	+	41	3	F	В	+	3,600	4.5	7.2	9.5	66	50	47	100
18.	29	0	+	40	2	М	0	+ (3,000	4.1	6.0	6.8	61	59	56	100
19	29	А	+	39	2	F	A	+	2,550	7.0	7.5	7.6	57	56	53	150
20.	30	В	+	40	2	F	AB	+	3,250	6.0	6.0	6.8	54	53	53	200
21.	26	0	+	38	3.	·M	0	+	3,490	5.9	8.7	10.8	64	57	51	50
22.	28	В	+	41	2	F	В	+ ,	2,900	6.2	8.5	10.0	57	51	47	200
23.	27	В	+	39	2	М	В	• +	3,050	5.9	8.6.	9.2	66	50	49	150
24.	35	0	+	40	2	M	0	+	3,230	7.0	9.7	10.0	70	62	57	150
25.	28	В	+	41	1	F	0	+	3,570	5.0	9.5	10.0	60	50	50	150
26.	28	0	+	38	1	F	0	+	3,150	5.8	9.6	12.0	74	64	58	200
27.	26	0	+	38	. 2	М	0	+	3,100	6.0	7.6	11.5	59	52	47	200
28.	29	В	+	38	3	F	В	+	3,610	9.0	11.0	12.5	63	61	59	100

Table 5. (cont.) Data of subject I group.

,	Mother's			gestational ages (week)	(x e e k) Infant's			s	bil:	mg.% irubin			Packe Is val		in	
				tati s (w						ag	es (ho	ur)	age	es (ho	ur);	ml. toci
no.	age	bl. gr.	Rh fact.	gest ages	grav	sex	bl. gr.	Rh fact.	body wt. (gm.)	24	48	72	24	48	72	ml. Oxytoci
29.	26	0.	+	40	3	F	0	+	2,550	7.0	8.0	8.5	51	47	46	90
30.	27	AB	+	41	. 1	F	A	+	2,830	7.4	8.6	11.2	75	69	. 64	50
31.	32	0	+	38	2.	F	0	+	2,790	6.7	7.9	8.5	53	45	45	100
32.	26 ·	В	+	42	1	F	В	+	3,110	6.2	8 . 5	10.0	73	55	50	200
33.	28	0	+'	39	2	F	0	+ //	3,140	7.5	9.4	9.5	70	62	62	150
34.	27	0	+	42	2	F	0	+	3,150	7.3	8.6	10.0	65	64	59	50




Table 6. Data of subject II group.

	Moth	er's		tional (week)			I1	nfant'	S	bi	mg.% lirubin			Paçke s volu		
				atic (we	gravida				laha .	ag	es (hou	r)	age	s (hou	r)	ml.
no.	age	bl. gr.	Rh fact.	gestational ages (week)	gra	sex	bl. gr.	Rh fact.	body wt. (gm.)	24	48	72	24	48	72	nl. Oxytocin
1.	26	В	+	40	1	. М	В	+	3,260	7.5	9.2	10.5	66	65	60	400
2.	27	В	`+	40	· 1	М	В	+	2,850	7.2	9.0	11.4	57	55	53	450
3.	-26	В	+	40	2	F	В	+	2,930	9.5	13.35	15.0	63	49	49	500
4.	27	A)	39	2	М	A	+	3,660	5.5	8.0	9.8	70	68	57	400
5.	32	В	+	39	. 1.	М	0	+ (3,120	7.0	10.0	11.5	61	. 55	. 55	500
6.	24	0	+	40	1	F.	Ο,	+	3,050	7.4	8.4	8.5	67	58	55	400
7.	30.	0	+ .	40	3	F	0	+	3,620	6.5	8.6	11.0	60	55	53	500
8.	21	A	+	39	1	F	A	+ .	3,610	9.7	10.5	11.0	55	54	52.	800
. 9.	27	В	+	40	1	F	В	+	2,980	7.0	12.5	15.25	70	64	65	700
10.	28	A	+	41	2	M	Α	+	3,150	7.0	8.4	10.4	67	61	55	800
11.	20	A	+	40	2	F	В	+	3,370	2.0	8.5	9.2	83	61	59	600
12.	28	В	+	41	3	F	0	• •	2,679	6.7	12.0	15.5	82	79	70	650
13.	23	ВЗ	+	40	1	М	В	+	3,560	3.0	9.2	11.0	88	73	66	1,100
14.	27	0	+	39	2	F	0.	+	3,050	7.4	9.0	11.1	60	60	58	1,200
15.	23	AB	+	40	1	F	В	+	2,620	7.0	9.5	11.0	74	59	59	800
16.	32	0	+	39	1	F	0	+	2,520	5.8	7.4	8.5	65	58	56	850

Table 7. Summerized data of the mothers' and infants'.

	Control	Subject I	Subject II
Number	51	34	16
Male : Female	25 : 26	12 : 22	6 : 10
Mean birth weight (grams)	3,091.37	3,198.82	3,126.81
Mean gestational ages	39.63	39.91	39.81
(weeks)			
Gravida :- 1st	25	9	9
Gravida :- 15t	20	18	5
	6	7	2
3rd	3.		
Blood group :-	1 3 4 <u>22 6 22 3 4</u>		4
Mother's A	.11	2	
В	19	17	7
AB	3	3	1
0	18	12	4
Infant's A	7	4	3
В	14	12	7
AB	5	2	_
0	25	16	6
Mean packed cell volume	าณมหา		
(%)			
:- 1st day	69.25	65.24	68.0
:- 2nd day	60.02	57.41	62.75
:- 3rd day	56.14	53.21	57.63
Mean mother's age	24.06	26.55	26.31
plean mounted 5 ago		·	

Figure 9. Histogram showing the frequency distribution of bilirubin concentration in babies of control group.



Figures 10. Histogram showing the frequency distribution of bilirubin concentration in babies of induced labour, subject I group.




Figure 11. Histogram showing the frequency distribution of bilirubin concentration in babies of induced labour, subject II group.




Figure 12. Comparison between mean serum bilirubin level on 1st, 2nd and 3rd days of ages, in control and subject I groups.




Figure 13. Comparison between mean serum bilirubin level on 1st, 2nd and 3rd days of ages, in control and subject II groups.




Table 8. Mean total bilirubin levels in mg. per 100 ml. (+ S.D.) in infants whose mothers were received oxytocin dose less than 4,000 milliunits (Subject I group), compared with control group.

Høurs	Control	Subject I
24	4.3686 + 1.2325	5.6588 <u>+</u> 1.4429
	(51)	(34)
48	7.5 <mark>833 + 0.7079</mark>	8.2912 <u>+</u> 1.2447
	(51)	(34)
72	9.5127 <u>+</u> 1.5049	9.9618 + 1.5208
	(51)	(34)

^{* =} significant difference, $P_0.001$.

^{** =} significant difference, P/0.01.

Table 9. Mean total bilirubin levels in mg. per 100 ml. (+ S.D.)
in infants whose mothers were received oxytocin dose more
over 4,000 milliunits (Subject II group), compared with
control group.

Hours	Control	Subject II
24	4.48 46 + 1.3287 (26)	6.6375 <u>+</u> 1.9507 * (16)
48	7.7058 ± 1.1146 (26)	9.5969 <u>+</u> 1.6880 * (16)
72	9.4269 <u>+</u> 1.5504 (26)	11.2906 <u>+</u> 2.1782** (16)

^{* =} significant difference, P/0.001.

^{** =} significant difference, P_0.01.

Figure 14. Comparison between mean serum bilirubin level on 1st, 2nd and 3rd days of ages in subject I and subject II groups.




Table 10. Mean total bilirubin Levels in mg. per 100 ml. (+ S.D.) in infants whose mother were received oxytocin dose more over 4,000 mU. (Subject II group) compared with infants whose mothers were received oxytocin dose less than 4,000 mU. (Subject I Group).

Hours	Subject I	Subject II
24	5.65 88 <u>+</u> 1.4429 (34)	6,6375 <u>+</u> 1.9507 (16)
48	8.2912 <u>+</u> 1.2447 (34)	9.5969 <u>+</u> 1.6880 ** (16)
72	9.9618 <u>+</u> 1.5208 (34)	11.2906 <u>+</u> 2.1782*** (16)

** = significant difference, P/0.01.

*** = significant difference, $P_0.05$.

Table 11. Summerized prescribed drugs of mothers in control group.

Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Ampicillin cap.s								-										 			
Biotaplex tab.	- 						v A														
Calfermin C tab.			,		/										 						/
Chlorpheniramine tab.			-														 				
Dumocycline cap.																					
Ferli-6 tab.		✓										_									
Fero-B-Cal tab.	- 	-	1	1		1			1		1		/	√	1			ļ		1	<u> </u>
Foliamin tab.															•				Ť		i
Gynecon vag. tab.																-					
Heminal tab.	V							/											}		/
Mycostatin vag. tab.															·						<u> </u>
Natabec cap.	V													·							
Natalin cap.	1.							V							<u> </u>		 -				
Paracetamol tab.	†																			<u> </u>	
Penicillin V tab.	†					,									-			<u> </u>			
Pethidine inj.												/									
Phenergan inj.	 				/	-	 -			- ,		`					··				-
Prutab tab.	<u> </u>													-							
Robitussin syr.			, .											<u>:</u>						<u> </u>	
Satibon tab.	-	/		/	7	/							/	_				<u>-</u> -			
Sultrin vag. tab.	+							<u> </u>					/	<u> </u>	V			<u> </u>	/		
Talsutrin vag. tab.	9		18	<u>, q</u>		7.5					9/				<u> </u>						
Vitamin C tab.				-											·		·				
Vitaplex tab.		1																		,	

Table 11. (cont.) Summerized prescribed drugs of mothers in control group.

Drugs	22	23	24	25	26	27	28	29	30	31	e ₃₂ .	33	34	35	36	37	38	39	40	41
Ampicillin cap.										<u> </u>			1	"						
Biotaplex cap.					1															
Calfermin C tab.	1	,	1	1		•		/	/			•		 		·		-		
Chlorpheniramine tab.	1	<u> </u>							/											
Dumocycline cap.								***** **** ****												
Ferli-6 tab.															-		-			
Fero-B-Cal tab.		1		٠.					/	1	,	/	1	1				ļ ———		/
Foliamin tab.																				
Gynecon vag. tab.						À														·/
Heminal tab.					/				/											
Mycostatin vag. tab.						9									<u> </u>					
Natabec cap.						44			/					/					/	
Natalin cap.																				
Paracetamol tab.			,		1			2/2/		-										
Penicillin V tab.					1		3/4								<u> </u>				,	
Pethidine inj.			24			/	/				4					V	$\overline{\mathcal{I}}$			
Phenergan inj.				,		/											-			
Prutab tab.	•															Ť		· .		-
Robitussin syr.					1			. ,												
Satibon tab.	6	1	/		1				V.	1		1	/		-		<u>-</u>			/
Sultrin vag. tab.					-									•						
Talsutrin. vag. tab.						. 6			<u>, , , , , , , , , , , , , , , , , , , </u>											
Vitamin C tab.			-1			18			1										-	
Vitaplex tab.),												•					,,,,,

Table 11. (cont.) Summerized prescribed drugs of mothers in control group.

Drugs	42	43	44	45	46	47	48	49	50	51	52	53
Ampicillin cap.										1		
Biotaplex tab.				- :.						<u> </u>		
Calfermin C tab.						·						-
Chlorpheniramine tab. Dumocycline cap.						•					-	
Ferli-6 tab.			-								-	
Fero-B-Cal tab.		1					/			<u> </u>	-	<u> </u>
Foliamin tab.						-				 	_	
Gynecon vag. tab.									·			
Heminal tab.			-	1		1						
Mycostatin vag. tab.												•
Natabec cap.			/									✓
Natalin cap.							/			/	· · · ·	
Paracetamol tab.							/					
Penicillin V tab.					5,,,,		1			-		
Pethidine inj.						44						
Phenergan inj.												
Prutab tab.		,		,				•				
Robitussin syr.	14.0										,	
Satibon tab.	1.0		0.0	V	0.0	/			/			•
Sultrin vag. tab.						d.	•					
Talsutrin vag. tab.			1	6.							w	
Vitamin C tab.	19	2	71			Я						
Vitaplex tab.										`		

Table 12. Summerized prescribed drugs of mothers in subject I group.

Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Ampicillin cap.					į																
Biotaplex tab.				,		N															
Calfermin C tab.																					
Chlorpheniramine tab.			1						•												
Dumocycline cap.													-								
Ferli-6 tab.			1																		
Fero-B-Cal tab.		1		/		/						-		/							
Foliamin tab.		-		·		1/2	_														
Gynecon vag. tab.																					
Heminal tab.	1	~			/	<u> </u>					-			,		/	1			✓	
Mycostatin vag. tab.										,	,					·					
Natabec cap.		1															· · ·	·			
Natalin cap.	/								1							1.	-/				
Paracetamol tab.										·											
Penicillin V tab.			/						-4-												
Pethidine inj.	1						1				/										
Phenergan inj.	1										V										
Prutab tab.											Ų.		7								
Robitussin				6 6				0.					,	,			1				
Satibon tab.		1	1	1		/								·/·			H	1			/
Sultrin vag. tab.													•				 	•			-
Talsutrin: vag. tab.	191	7	3.0	n			0]	0.Ω	~ 4		Λø					-		·			
Vitamin C tab.									,	6 1	-	-								·	-
Vitaplex tab.	<u> </u>				 					· -				-			_		-		-

Table 12. (Cont.) Summerized	pre	escr	ibec	dr	ugs	of 1	noth	ers	in	subj	ect	Ιg	roup
Drugs	22	23	24	25	26	27	28	29	30	31	32	33	34
Ampicillin cap.					1					†	ļ	†	
Biotaplex tab.					·				1		-		:
Calfermin C tab.					1						/		7
Chlorpheniramine tab.										 		 	
Dumocycline cap.			-						-			<u> </u>	
Ferli-6 tab.				,					ļ		/		/
Fero-B-Cal tab.				1					/	1			
Foliamin tab.													
Gynecon vag. tab.			1/3/						<u> </u>				
Heminal tab.		1	1				/	/					
Mycostatin vag. tab.								-				\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
Natabec cap.	/				1								·
Natalin cap.		1	/	1/2				/				•	./
Paracetamol tab.			(4)										<u> </u>
Penicillin V tab.		A					·						
Pethidine inj.						/			/	-			
Phenergan inj.		·		ļ		· /							
Prutab tab.										·			
Robitussin syr.													
Satibon tab.		9/	10	1			./	7.9	./			\rightarrow	
Sultrin vag. tab.							-		-			×	
Talsutrin, vag. tab.		-		0 1									
Vitamin C tab.		_	1										
Vitaplex tab.								-			<u> </u>		

Table 13. Summerized prescribed drugs of mothers in subject II group.

Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Ampicillin cap.s																
Biotaplex tab.					1											
Calfermin C tab.				1				`								
Chlorpheniramine tab.			/						-						1	
Dumocycline cap.		,				-			-					<u> </u>		
Ferli-6 tab.					7									-		
Fero-B-Cal tab.							1	/	1		<u> </u>					
Foliamin tab.										<u>`</u>			 	-		
Gynecon vag. tab.															_	
Heminal tab.		/			1										1	/
Mycostatin vag. tab.									/						-	
Natabec cap.	*-			1			1				1					``
Natalin cap.	V	1				_										
Paracetamol tab.						-										
Penicillin V tab.																
Pethidine inj.	V				1	1				7						/
Phenergan inj.	1					/	-									
Prutab tab.				/					1							
Robitussin syr.	4									٠.						
Satibon tab.	1.0					1	1					/	7			
Sultrin vag. tab.	1											,				
Tasutrin_ vag. tab.			5	a	91	9,9	\cap					9				
Vitamin C tab.															/	
Vitaplex tab.							- 1							,		